Latest Insider Transactions at Hca Healthcare, Inc. (HCA)
This section provides a real-time view of insider transactions for Hca Healthcare, Inc. (HCA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HCA Healthcare, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HCA Healthcare, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2023
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Open market or private sale
|
Direct |
1,734
-14.83%
|
$456,042
$263.61 P/Share
|
|
Feb 17
2023
|
Christopher F. Wyatt SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
2,393
-6.22%
|
$626,966
$262.84 P/Share
|
|
Feb 17
2023
|
Christopher F. Wyatt SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
6,080
+13.65%
|
-
|
|
Feb 17
2023
|
Samuel N Hazen CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
36,770
-18.33%
|
$9,633,740
$262.84 P/Share
|
|
Feb 17
2023
|
Samuel N Hazen CEO |
BUY
Grant, award, or other acquisition
|
Direct |
94,880
+32.12%
|
-
|
|
Feb 17
2023
|
Mike A Marks EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,847
-17.69%
|
$483,914
$262.84 P/Share
|
|
Feb 17
2023
|
Mike A Marks EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
6,080
+36.8%
|
-
|
|
Feb 17
2023
|
Timothy M Mc Manus Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,438
-11.29%
|
$638,756
$262.84 P/Share
|
|
Feb 17
2023
|
Timothy M Mc Manus Group President |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+26.04%
|
-
|
|
Feb 17
2023
|
Sammie S Mosier SVP & Chief Nurse Executive |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-3.39%
|
$71,526
$262.84 P/Share
|
|
Feb 17
2023
|
Sammie S Mosier SVP & Chief Nurse Executive |
BUY
Grant, award, or other acquisition
|
Direct |
1,120
+12.2%
|
-
|
|
Feb 17
2023
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,589
-11.48%
|
$940,318
$262.84 P/Share
|
|
Feb 17
2023
|
P. Martin Paslick SVP and CIO |
BUY
Grant, award, or other acquisition
|
Direct |
9,120
+22.58%
|
-
|
|
Feb 17
2023
|
Deborah M Reiner SVP - Mktg. & Communications |
SELL
Payment of exercise price or tax liability
|
Direct |
1,246
-27.32%
|
$326,452
$262.84 P/Share
|
|
Feb 17
2023
|
Deborah M Reiner SVP - Mktg. & Communications |
BUY
Grant, award, or other acquisition
|
Direct |
4,560
+50.0%
|
-
|
|
Feb 17
2023
|
Bill B Rutherford CFO and EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
9,563
-9.03%
|
$2,505,506
$262.84 P/Share
|
|
Feb 17
2023
|
Bill B Rutherford CFO and EVP |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+18.66%
|
-
|
|
Feb 17
2023
|
Phillip G Billington SVP-Internal Audit Services |
SELL
Payment of exercise price or tax liability
|
Direct |
1,247
-2.76%
|
$326,714
$262.84 P/Share
|
|
Feb 17
2023
|
Phillip G Billington SVP-Internal Audit Services |
BUY
Grant, award, or other acquisition
|
Direct |
4,560
+9.16%
|
-
|
|
Feb 17
2023
|
Jeffrey E. Cohen SVP-Government Relations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,652
-21.83%
|
$432,824
$262.84 P/Share
|
|
Feb 17
2023
|
Jeffrey E. Cohen SVP-Government Relations |
BUY
Grant, award, or other acquisition
|
Direct |
4,560
+37.61%
|
-
|
|
Feb 17
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,232
-12.83%
|
$1,108,784
$262.84 P/Share
|
|
Feb 17
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,160
+26.94%
|
-
|
|
Feb 17
2023
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,768
-25.32%
|
$2,035,216
$262.84 P/Share
|
|
Feb 17
2023
|
Jon M Foster EVP and COO |
BUY
Grant, award, or other acquisition
|
Direct |
19,740
+39.15%
|
-
|
|
Feb 17
2023
|
Richard A Hammett Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,414
-18.68%
|
$894,468
$262.84 P/Share
|
|
Feb 17
2023
|
Richard A Hammett Group President |
BUY
Grant, award, or other acquisition
|
Direct |
9,680
+22.81%
|
-
|
|
Feb 17
2023
|
Erol R Akdamar Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,110
-6.33%
|
$814,820
$262.84 P/Share
|
|
Feb 17
2023
|
Erol R Akdamar Group President |
BUY
Grant, award, or other acquisition
|
Direct |
9,300
+15.93%
|
-
|
|
Feb 17
2023
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,441
-16.28%
|
$639,542
$262.84 P/Share
|
|
Feb 17
2023
|
Jennifer Berres SVP & Chief Human Res. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+33.64%
|
-
|
|
Feb 16
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,467
-9.89%
|
$648,821
$263.15 P/Share
|
|
Feb 16
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Exercise of conversion of derivative security
|
Direct |
4,575
+15.5%
|
$462,075
$101.16 P/Share
|
|
Feb 07
2023
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Open market or private sale
|
Direct |
4,000
-35.11%
|
$1,020,000
$255.23 P/Share
|
|
Feb 03
2023
|
Samuel N Hazen CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
32,208
-23.36%
|
$8,309,664
$258.08 P/Share
|
|
Feb 03
2023
|
Samuel N Hazen CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,000
+29.97%
|
$4,012,000
$68.96 P/Share
|
|
Feb 03
2023
|
Sammie S Mosier SVP & Chief Nurse Executive |
SELL
Payment of exercise price or tax liability
|
Direct |
41
-0.59%
|
$10,578
$258.08 P/Share
|
|
Feb 03
2023
|
Sammie S Mosier SVP & Chief Nurse Executive |
BUY
Exercise of conversion of derivative security
|
Direct |
138
+1.94%
|
-
|
|
Feb 03
2023
|
Deborah M Reiner SVP - Mktg. & Communications |
SELL
Open market or private sale
|
Direct |
7,941
-100.0%
|
$2,040,837
$257.61 P/Share
|
|
Feb 03
2023
|
Erol R Akdamar Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,932
-8.99%
|
$1,014,456
$258.08 P/Share
|
|
Feb 03
2023
|
Erol R Akdamar Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+17.07%
|
$405,000
$45.3 P/Share
|
|
Feb 03
2023
|
Bill B Rutherford CFO and EVP |
SELL
Open market or private sale
|
Direct |
30,000
-26.87%
|
$7,740,000
$258.19 P/Share
|
|
Feb 02
2023
|
Erol R Akdamar Group President |
SELL
Open market or private sale
|
Direct |
3,000
-7.95%
|
$774,000
$258.63 P/Share
|
|
Feb 01
2023
|
Bill B Rutherford CFO and EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
34,895
-23.81%
|
$9,107,595
$261.46 P/Share
|
|
Feb 01
2023
|
Bill B Rutherford CFO and EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
64,000
+19.6%
|
$4,416,000
$69.27 P/Share
|
|
Feb 01
2023
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
586
-4.77%
|
$149,430
$255.07 P/Share
|
|
Feb 01
2023
|
Christopher F. Wyatt SVP & Controller |
SELL
Open market or private sale
|
Direct |
4,900
-13.14%
|
$1,239,700
$253.3 P/Share
|
|
Feb 01
2023
|
P. Martin Paslick SVP and CIO |
SELL
Open market or private sale
|
Indirect |
1,000
-25.0%
|
$256,000
$256.95 P/Share
|
|
Feb 01
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
4,000
-16.11%
|
$1,028,000
$257.11 P/Share
|
|
Feb 01
2023
|
Jon M Foster EVP and COO |
SELL
Open market or private sale
|
Direct |
16,424
-60.02%
|
$4,122,424
$251.98 P/Share
|